Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26132263 | 0.98 | CACNA1H (0.59) | CACNA1H | |
| SCHEMBL26131246 | 0.78 | CACNA1H (0.55) | CACNA1H | |
| SCHEMBL18686490 | 0.76 | CACNA1H (0.80) | CACNA1H | |
| SCHEMBL18686562 | 0.76 | CACNA1H (0.80) | CACNA1H | |
| SCHEMBL18686492 | 0.76 | CACNA1H (0.80) | CACNA1H | |
| Hydrochloric Acid SCHEMBL18686586 | 0.75 | CACNA1H (0.67) | CACNA1H | |
| Hydrochloric Acid SCHEMBL18686634 | 0.75 | CACNA1H (0.67) | CACNA1H | |
| SCHEMBL18686491 | 0.75 | CACNA1H (0.71) | CACNA1H | |
| Hydrochloric Acid SCHEMBL18686584 | 0.75 | CACNA1H (0.67) | CACNA1H | |
| SCHEMBL18686489 | 0.75 | CACNA1H (0.71) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213558-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-119278038-A | T-type calcium channel modulators comprising piperazine or 1, 4-diazacycloheptane cores and methods of use thereof | 普拉西斯精密医药公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2023192669-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192669-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213558-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | CACNA1G, CACNA1I, CACNA1H | CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.